Tempest reports early Phase 1 clinical activity for CAR-T candidate in multiple myeloma
TPST•TPST•TPST•TPST•Tempest Therapeutics exercised its option to license Senlang’s CD7-targeted lentiviral CAR-T platform, securing exclusive global rights outside China. The company cited preliminary activity and tolerability observations from a 13-patient Phase 1 trial of its TPST-4903 candidate, with detailed results planned for a scientific conference.
Tempest Therapeutics exercised its option to license Senlang’s CD7-targeted lentiviral CAR-T platform, securing exclusive global rights outside China. Its lead candidate, TPST-4903, targets BCMA/GPRC5D and is being studied in the DELIVER-1 Phase 1 trial, which treated 13 patients with relapsed or refractory multiple myeloma. The company said preliminary clinical activity and tolerability observations supported the licensing decision, while noting longer follow-up is needed to assess benefits and risks; detailed results are planned for presentation at a major scientific conference.
